Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

AZTR vs QNCX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AZTR
Azitra, Inc.

Biotechnology

HealthcareAMEX • US
Market Cap$3M
5Y Perf.-100.0%
QNCX
Quince Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$7M
5Y Perf.-91.4%

AZTR vs QNCX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AZTR logoAZTR
QNCX logoQNCX
IndustryBiotechnologyBiotechnology
Market Cap$3M$7M
Revenue (TTM)$0.00$0.00
Net Income (TTM)$-11M$-84M
Total Debt$422M$18M
Cash & Equiv.$2.07B$6M

AZTR vs QNCXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AZTR
QNCX
StockJun 23May 26Return
Azitra, Inc. (AZTR)1000.0-100.0%
Quince Therapeutics… (QNCX)1008.6-91.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: AZTR vs QNCX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: AZTR leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Quince Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
AZTR
Azitra, Inc.
The Income Pick

AZTR carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • beta 0.40
  • Lower volatility, beta 0.40, Low D/E 11.1%, current ratio 2.83x
  • Beta 0.40, current ratio 2.83x
Best for: income & stability and sleep-well-at-night
QNCX
Quince Therapeutics, Inc.
The Growth Play

QNCX is the clearest fit if your priority is growth exposure and long-term compounding.

  • EPS growth -28.2%
  • -99.6% 10Y total return vs AZTR's -100.0%
  • -48.0% revenue growth vs AZTR's -100.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthQNCX logoQNCX-48.0% revenue growth vs AZTR's -100.0%
Quality / MarginsQNCX logoQNCX1.3% margin vs AZTR's 0.0%
Stability / SafetyAZTR logoAZTRBeta 0.40 vs QNCX's 2.23
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)AZTR logoAZTR-87.4% vs QNCX's -87.5%
Efficiency (ROA)AZTR logoAZTR-0.2% ROA vs QNCX's -78.5%, ROIC -0.8% vs -485.6%

AZTR vs QNCX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLAZTRLAGGINGQNCX

Income & Cash Flow (Last 12 Months)

QNCX leads this category, winning 1 of 1 comparable metric.

AZTR and QNCX operate at a comparable scale, with $0 and $0 in trailing revenue.

MetricAZTR logoAZTRAzitra, Inc.QNCX logoQNCXQuince Therapeuti…
RevenueTrailing 12 months$0$0
EBITDAEarnings before interest/tax-$11M-$50M
Net IncomeAfter-tax profit-$11M-$84M
Free Cash FlowCash after capex-$86M-$48M
Gross MarginGross profit ÷ Revenue
Operating MarginEBIT ÷ Revenue
Net MarginNet income ÷ Revenue
FCF MarginFCF ÷ Revenue
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year-6.9%-167.9%
QNCX leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

AZTR leads this category, winning 1 of 1 comparable metric.
MetricAZTR logoAZTRAzitra, Inc.QNCX logoQNCXQuince Therapeuti…
Market CapShares × price$3M$7M
Enterprise ValueMkt cap + debt − cash-$1.6B$20M
Trailing P/EPrice ÷ TTM EPS-0.11x-0.08x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue
Price / BookPrice ÷ Book value/share0.00x
Price / FCFMarket cap ÷ FCF
AZTR leads this category, winning 1 of 1 comparable metric.

Profitability & Efficiency

AZTR leads this category, winning 4 of 5 comparable metrics.
MetricAZTR logoAZTRAzitra, Inc.QNCX logoQNCXQuince Therapeuti…
ROE (TTM)Return on equity-0.3%
ROA (TTM)Return on assets-0.2%-78.5%
ROICReturn on invested capital-0.8%-4.9%
ROCEReturn on capital employed-0.6%-64.0%
Piotroski ScoreFundamental quality 0–911
Debt / EquityFinancial leverage0.11x
Net DebtTotal debt minus cash-$1.6B$13M
Cash & Equiv.Liquid assets$2.1B$6M
Total DebtShort + long-term debt$422M$18M
Interest CoverageEBIT ÷ Interest expense-13.79x
AZTR leads this category, winning 4 of 5 comparable metrics.

Total Returns (Dividends Reinvested)

QNCX leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in QNCX five years ago would be worth $35 today (with dividends reinvested), compared to $2 for AZTR. Over the past 12 months, AZTR leads with a -87.4% total return vs QNCX's -87.5%. The 3-year compound annual growth rate (CAGR) favors QNCX at -57.0% vs AZTR's -93.8% — a key indicator of consistent wealth creation.

MetricAZTR logoAZTRAzitra, Inc.QNCX logoQNCXQuince Therapeuti…
YTD ReturnYear-to-date-14.8%-95.7%
1-Year ReturnPast 12 months-87.4%-87.5%
3-Year ReturnCumulative with dividends-100.0%-92.0%
5-Year ReturnCumulative with dividends-100.0%-99.6%
10-Year ReturnCumulative with dividends-100.0%-99.6%
CAGR (3Y)Annualised 3-year return-93.8%-57.0%
QNCX leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

AZTR leads this category, winning 2 of 2 comparable metrics.

AZTR is the less volatile stock with a 0.40 beta — it tends to amplify market swings less than QNCX's 2.23 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AZTR currently trades 9.9% from its 52-week high vs QNCX's 2.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAZTR logoAZTRAzitra, Inc.QNCX logoQNCXQuince Therapeuti…
Beta (5Y)Sensitivity to S&P 5000.40x2.23x
52-Week HighHighest price in past year$2.40$45.50
52-Week LowLowest price in past year$0.10$0.80
% of 52W HighCurrent price vs 52-week peak+9.9%+2.9%
RSI (14)Momentum oscillator 0–10057.441.6
Avg Volume (50D)Average daily shares traded13.6M49.5M
AZTR leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricAZTR logoAZTRAzitra, Inc.QNCX logoQNCXQuince Therapeuti…
Analyst RatingConsensus buy/hold/sell
Price TargetConsensus 12-month target
# AnalystsCovering analysts
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

AZTR leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). QNCX leads in 2 (Income & Cash Flow, Total Returns).

Best OverallAzitra, Inc. (AZTR)Leads 3 of 6 categories
Loading custom metrics...

AZTR vs QNCX: Frequently Asked Questions

7 questions · data-driven answers · updated daily

01

Which is the better long-term investment — AZTR or QNCX?

Over the past 5 years, Quince Therapeutics, Inc.

(QNCX) delivered a total return of -99. 6%, compared to -100. 0% for Azitra, Inc. (AZTR). Over 10 years, the gap is even starker: QNCX returned -99. 6% versus AZTR's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

02

Which is safer — AZTR or QNCX?

By beta (market sensitivity over 5 years), Azitra, Inc.

(AZTR) is the lower-risk stock at 0. 40β versus Quince Therapeutics, Inc. 's 2. 23β — meaning QNCX is approximately 456% more volatile than AZTR relative to the S&P 500.

03

Which is growing faster — AZTR or QNCX?

On earnings-per-share growth, the picture is similar: Quince Therapeutics, Inc.

grew EPS -28. 2% year-over-year, compared to -532. 3% for Azitra, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

04

Which has better profit margins — AZTR or QNCX?

Azitra, Inc.

(AZTR) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Quince Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZTR leads at 0. 0% versus 0. 0% for QNCX. At the gross margin level — before operating expenses — AZTR leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

05

Which pays a better dividend — AZTR or QNCX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

06

Is AZTR or QNCX better for a retirement portfolio?

For long-horizon retirement investors, Azitra, Inc.

(AZTR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 40)). Quince Therapeutics, Inc. (QNCX) carries a higher beta of 2. 23 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AZTR: -100. 0%, QNCX: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

07

What are the main differences between AZTR and QNCX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

AZTR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

QNCX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.